CN205515128U - Can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma - Google Patents
Can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma Download PDFInfo
- Publication number
- CN205515128U CN205515128U CN201620232104.XU CN201620232104U CN205515128U CN 205515128 U CN205515128 U CN 205515128U CN 201620232104 U CN201620232104 U CN 201620232104U CN 205515128 U CN205515128 U CN 205515128U
- Authority
- CN
- China
- Prior art keywords
- angle
- support body
- hysteromyoma
- del
- tailfiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model provides a contraception effect can be treated again that can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma, the present intrauterine device of main solution can not play existing well and a problem that prevents the hysteromyoma the utility model provides a can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma, including the support body, the support body is for falling triangle -shaped, the support body includes the lateral frame, first support body, second support body, angle A, angle B, angle C, tailfiber hole, tailfiber and contain the silica gel cover of SULT1E1 plasmid. The utility model discloses an intrauterine device had not only reached good contraception effect but also can treat and prevent the effect of this gynaecology's common disease of hysteromyoma.
Description
Technical field
This utility model relates to a kind of intrauterine device, can prevent and treat hysteromyoma particularly to one
Del intrauterine device, belong to medical apparatus preparation field.
Background technology
Uterus is the direct target organ of Estrogen and progestin, and the generation of various gynecological tumors is with female, pregnant
Hormonal readiness is closely related.Current research shows, tissue local estrogen synthesis and metabolism are different
Often, causing estrogen accumulation is the major reason that estrogen-dependent diseases occurs development.For
Existing research, reduces tissue local estrogen concentrations and becomes the new breakthrough point treating this kind of disease.
Hysteromyoma is the modal benign tumor of gynecological, and women at fertile age sickness rate is about
20%-25%, accounts for female sex organs carcinoid 52%, so China exists substantial amounts of patient
Basis.The Drug therapy of hysteromyoma is many at present regulates with hormonotherapy and selectivity hormone receptor
Agent and somatomedin regulator are main, but all can not thoroughly cure hysteromyoma.And intramuscular injection and mouth
The administering mode side effect such as clothes are obvious, and therapeutic effect is limited.
Sulfating reaction is the important channel making gonadal hormone inactivate.SULT1E1 is to be found at present
10 kinds of isozymes in the enzyme the strongest to estrogen catalytic action, as important removing toxic substances enzyme,
Catalysis estrogen sulphation metabolism, forms the inactive sulfated estrogens of water solublity, it is possible to decrease follow
And target tissue estrogen exposure level.Wang Min and Wu Haili et al. is confirmed by research, SULT1E1
In Human Leiomyma, take up the low expression of normal uterine tissue compared with muscular tumor, cause endogenous female sharp
Element level raises, and estrogen can raise progesterone receptor content, and then promote hysteromyoma
Growth.Therefore strengthen SULT1E1 activity and just can suppress the estrogen facilitation to muscular tumor,
Suppression muscular tumor occurs, development.Other estrogen-dependent tumor also there is certain therapeutical effect.
Report is had no at present about this intrauterine device containing SULT1E1.And, at present
Conventional is also the most simple copper intrauterine devices clinically, it is impossible to enough play existing good
The effect of this common gynecological disease of hysteromyoma can be treated and prevent again to contraceptive effect.
Utility model content
For the problems referred to above, technical problem to be solved in the utility model is that offer one can
The del intrauterine device of preventing and treating hysteromyoma, has not only reached good contraceptive effect but also can
With treatment and the effect of prevention this common gynecological disease of hysteromyoma.
In order to solve above-mentioned technical problem, the technical solution adopted in the utility model is as follows:
A kind of del intrauterine device preventing and treating hysteromyoma, including rack body, institute
Stating rack body is del, and described rack body includes lateral frame, the first support body, second
Support body, angle A, angle B, angle C, tailfiber hole, tailfiber and the silica gel containing SULT1E1 plasmid
Set；Described lateral frame two ends are provided with described angle A with the first support body and the second support body junction respectively
And described angle B, the junction, bottom of the first support body and the second support body is provided with described angle C, described
Angle A, angle B and angle C are blunt round, and the described silica gel sheath containing SULT1E1 plasmid holds
Outside whole described rack body, described angle C is provided with described tailfiber hole, described tailfiber hole
Place connects described tailfiber.
Further, described rack body is titanium alloy support.
Further, described rack body is equilateral del structure.
Further, described lateral frame, the first support body, the second support body are and concave towards support central authorities
Arcuate structure.
Further, the described silica gel sheath containing SULT1E1 plasmid is medical silica-gel.
The beneficial effects of the utility model:
Intrauterine device of the present utility model has the advantage that
(1) del of the present utility model design meets uterine cavity shape, difficult drop-off.
(2) the high SULTE1E in endometrium local causes intrauterine low estrogen environment, no
Suitable germ cell implantation, thus reach contraceptive effect.
(3) blunt round design, not easy damaged endometrium and uterus it are at each angle of triangle
Muscle layer, side effect is less.
(4) whole rack body i.e. support three limit and three angles are loaded with containing SULT1E1 plasmid
Silica gel sheath, can directly discharge SULT1E1 and act in uterine cavity or muscular tumor local, medicine-feeding part
Definitely, it is to avoid untoward reaction that Formulations for systemic administration causes and side effect.According to its action principle not
It is only capable of playing the effect for the treatment of hysteromyoma, more can play prevention and even treat carcinoma of endometrium
Effect.
(5) design of triangle, maximizes the space being loaded with SULT1E1 plasmid, medicine carrying
Amount designs much larger than T-shaped, substantially increases the service life of medicated intrauterine devices.
(6) the tailfiber design of lower end, it is simple to the taking-up of intrauterine device.
Accompanying drawing explanation
Fig. 1 is structural representation of the present utility model.
Detailed description of the invention
In order to make the purpose of this utility model, technical scheme and advantage clearer, below
In conjunction with drawings and Examples, this utility model is further elaborated.Should be appreciated that
Specific embodiment described herein, only in order to explain this utility model, is not used to limit this
Utility model.
As it is shown in figure 1, a kind of del intrauterine device preventing and treating hysteromyoma, including
Rack body 1, for the equilateral del support of titanium alloy, del structure meets uterine cavity
Form, difficult drop-off, rack body 1 includes lateral frame 2, the first support body 3, the second support body
4, angle A5, angle B6, angle C7, tailfiber hole 8, tailfiber 9 and the silicon containing SULT1E1 plasmid
Gum cover 10；The two ends of lateral frame 2 set with the first support body 3 and the second support body 4 junction respectively
Angle A5 and angle B6, the junction, bottom of the first support body 3 and the second support body 4 is had to be provided with angle C7,
Described angle A5, angle B6 and angle C7 are blunt round, not easy damaged endometrium and uterus muscle
Layer, side effect is less, and lateral frame the 2, first support body the 3, second support body 4 is and concaves towards support
The arc of central authorities.Silica gel sheath 10 containing SULT1E1 plasmid surrounds whole rack body 1
Outside, and be medical silica-gel containing the silica gel sheath of SULT1E1 plasmid, can directly discharge SULT1E1
Act in uterine cavity or muscular tumor local, medicine-feeding part is definite, it is to avoid Formulations for systemic administration causes not
Good reaction and side effect, angle C7 is provided with tailfiber hole 8, connects described tailfiber 9 at tailfiber hole 8.
The design of overall triangle, maximizes the space being loaded with SULT1E1 plasmid, and drug loading is long-range
Designing in T-shaped, substantially increase the service life of medicated intrauterine devices, the tailfiber of lower end sets
Meter, it is simple to the taking-up of intrauterine device.
The foregoing is only preferred embodiment of the present utility model, not in order to limit this reality
With novel, all made within spirit of the present utility model and principle any amendment, equivalent replace
Change and improvement etc., within should be included in protection domain of the present utility model.
Claims (5)
1. can prevent and treat a del intrauterine device for hysteromyoma, including rack body,
Described rack body is del, it is characterised in that described rack body includes lateral frame,
First support body, the second support body, angle A, angle B, angle C, tailfiber hole, tailfiber and containing SULT1E1
The silica gel sheath of plasmid；Described lateral frame two ends set with the first support body and the second support body junction respectively
Having described angle A and described angle B, the junction, bottom of the first support body and the second support body is provided with described
Angle C, described angle A, angle B and angle C be blunt round, described containing SULT1E1 plasmid
Silica gel sheath surrounds outside whole described rack body, and described angle C is provided with described tailfiber hole,
Described tailfiber is connected at described tailfiber hole.
A kind of del preventing and treating hysteromyoma in utero saves
Educate device, it is characterised in that described rack body is titanium alloy support.
A kind of del preventing and treating hysteromyoma in utero saves
Educate device, it is characterised in that described rack body is equilateral del structure.
A kind of del preventing and treating hysteromyoma in utero saves
Educate device, it is characterised in that described lateral frame, the first support body, the second support body are and concave towards support
The arcuate structure of central authorities.
A kind of del preventing and treating hysteromyoma in utero saves
Educate device, it is characterised in that the described silica gel sheath containing SULT1E1 plasmid is medical silica-gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620232104.XU CN205515128U (en) | 2016-03-24 | 2016-03-24 | Can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620232104.XU CN205515128U (en) | 2016-03-24 | 2016-03-24 | Can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN205515128U true CN205515128U (en) | 2016-08-31 |
Family
ID=56783694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201620232104.XU Expired - Fee Related CN205515128U (en) | 2016-03-24 | 2016-03-24 | Can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN205515128U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106473859A (en) * | 2016-11-04 | 2017-03-08 | 郑州莉迪亚医药科技有限公司 | A kind of adjustable intrauterine device |
| CN109758622A (en) * | 2018-04-19 | 2019-05-17 | 易浦润（上海）生物技术有限公司 | A kind of elastic membrane |
| CN112494189A (en) * | 2020-11-03 | 2021-03-16 | 北京科技大学 | Degradable metal uterine cavity stent and release system and use method |
-
2016
- 2016-03-24 CN CN201620232104.XU patent/CN205515128U/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106473859A (en) * | 2016-11-04 | 2017-03-08 | 郑州莉迪亚医药科技有限公司 | A kind of adjustable intrauterine device |
| CN106473859B (en) * | 2016-11-04 | 2018-10-30 | 张美娟 | A kind of adjustable intrauterine device |
| CN109758622A (en) * | 2018-04-19 | 2019-05-17 | 易浦润（上海）生物技术有限公司 | A kind of elastic membrane |
| CN109758622B (en) * | 2018-04-19 | 2021-08-06 | 易浦润（上海）生物技术有限公司 | Elastic film |
| CN112494189A (en) * | 2020-11-03 | 2021-03-16 | 北京科技大学 | Degradable metal uterine cavity stent and release system and use method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN205515128U (en) | Can prevent and treat triangle -shaped intrauterine device that falls of hysteromyoma | |
| TWI224002B (en) | Pharmaceutical compositions for treating prostate hypertrophy and prostate cancer | |
| Loeser | Subcutaneous implantation of female and male hormone in tablet form in women | |
| PT1539184E (en) | Estrogen replacement regimen | |
| Azim et al. | Breast-feeding after breast cancer: if you wish, madam | |
| CN105078642B (en) | A kind of uterus implant | |
| Laron et al. | D-Trp6-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty | |
| Richard | Endocrine therapy for breast cancer | |
| ES2247710T3 (en) | GONADOTROPINE ANTAGONIST. | |
| CN205494630U (en) | Prevent sacculus uterus support of oppression | |
| CN105194642A (en) | Composition for dredging breast microcirculation to maintain autologous glandular cells and preparation method thereof | |
| CN109700558A (en) | A kind of ewe uterus reset auxiliary therapeutic apparatus | |
| CN111297910B (en) | Application of five-cereal worms in preparation of medicaments for preventing and treating hyperplasia of mammary glands | |
| Bhatnagar et al. | Long-term contraception by steroid-releasing implants. II A preliminary report on long-term contraception by a single silastic implant containing norethindrone acetate (ENTA) in women | |
| CN103055083A (en) | Chinese medicine for treating women dysmenorrhea and preparation method of external patch of Chinese medicine | |
| CN103893336B (en) | A kind of Chinese medicinal enema treating qi stagnation and blood stasis type oviduct obstructive sterility and care method | |
| CN104739956A (en) | Use of traditional Chinese medicine composition in preparing antiandrogen drug | |
| McLafferty et al. | Male and female reproductive systems and associated conditions | |
| CN103598944B (en) | Reversibility medicine carrying common oviduct IUD | |
| CN201012136Y (en) | Vagina targeting drug administration device | |
| CN108853007B (en) | A kind of gel preparation and application thereof for treating functional uterine bleeding | |
| CN102988401B (en) | Application of adenosine triphosphate or medicinal salt of adenosine triphosphatein in preparation of medicine for treating endometriosis | |
| CN204745334U (en) | Memory alloy silica gel is slow release system in utero | |
| EP2978435B1 (en) | A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome | |
| MX2010011063A (en) | Steroid treatment for hot flashes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160831 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |